Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Severe COVID-19 Patients


Citar

Texto integral

Resumo

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), was declared a global pandemic in March 2020 and resulted in more than 6 million deaths worldwide to date. Although several vaccines were produced against COVID-19 and many therapeutic protocols were developed for the management of this respiratory infection, COVID-19 pandemic has still remained an unresolved problem with the emergence of new variants of SARS-CoV-2, especially vaccine-resistant variants. Probably, end of the COVID-19 needs effective and certain treatments which were undiscovered to date. According to immunomodulatory and regenerative properties, mesenchymal stem cells (MSCs) have been considered a therapeutic approach to suppressing cytokine storm caused by SARS-CoV-2 and the treatmet of severe COVID-19. Following intravenous (IV) infusion of MSCs, cells entrap in the lung, guard alveolar epithelial cells, suppress pulmonary fibrosis and improve lung dysfunction. The human menstrual blood-derived stem cells (hMenSCs) as a novel source of MSCs are collected by noninvasive, painless, and easy way without ethical issues. MenScs are an abundant and cheap source with a high proliferation rate and differentiation ability into multiple cell lineages. Regarding immunomodulatory and anti-inflammatory properties, regenerative ability and low immunogenicity, these cells exhibit great potential in the treatment of various diseases. Some clinical trial studies have begun using MenSCs to treat severe COVID-19. According to these trials, MenSC therapy showed promising and encouraging results in treating severe COVID-19. We reviewed published clinical trials and summarized the effects of MenSC therapy on severe COVID-19 with a focus on clinical and laboratory data, immune and inflammatory factors and concluded the advantages and possible risks of this procedure.

Sobre autores

Fezzeh Heidari

Medical Biotechnology Research Center, AJA University of Medical Sciences

Email: info@benthamscience.net

Reza Heidari

Medical Biotechnology Research Center, AJA University of Medical Sciences

Email: info@benthamscience.net

Mehrdad Sabet

Research Center for Cancer Screening and Epidemiology, Aja University of Medical Sciences

Email: info@benthamscience.net

Amir Hamidieh

Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences

Email: info@benthamscience.net

Zohreh Saltanatpour

Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5 PMID: 31986264
  2. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199-207. doi: 10.1056/NEJMoa2001316 PMID: 31995857
  3. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ 2020; 368: m606. doi: 10.1136/bmj.m606 PMID: 32075786
  4. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: Present or future. Stem Cell Rev Rep 2020; 16(3): 427-33. doi: 10.1007/s12015-020-09973-w PMID: 32281052
  5. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet 2021; 397(10278): 952-4. doi: 10.1016/S0140-6736(21)00370-6 PMID: 33581803
  6. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med 2021; 385(7): 585-94. doi: 10.1056/NEJMoa2108891 PMID: 34289274
  7. Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 viral variants-Tackling a moving target. JAMA 2021; 325(13): 1261-2. doi: 10.1001/jama.2021.2088 PMID: 33571363
  8. Durand N, Mallea J, Zubair AC. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. NPJ Regen Med 2020; 5(1): 17. doi: 10.1038/s41536-020-00105-z PMID: 33580031
  9. Gao F, Chiu SM, Motan D A L, et al. Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis 2016; 7(1): e2062. doi: 10.1038/cddis.2015.327 PMID: 26794657
  10. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 2012; 18(2): 128-34. doi: 10.1016/j.molmed.2011.10.004 PMID: 22118960
  11. Shi M, Liu Z, Wang Y, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Transl Med 2017; 6(12): 2053-61. doi: 10.1002/sctm.17-0134 PMID: 29178564
  12. Chen L, Qu J, Cheng T, Chen X, Xiang C. Menstrual blood-derived stem cells: Toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther 2019; 10(1): 406. doi: 10.1186/s13287-019-1503-7 PMID: 31864423
  13. Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: Multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 2017; 6(12): 2173-85. doi: 10.1002/sctm.17-0129 PMID: 29076267
  14. Golchin A, Farahany TZ, Khojasteh A, Soleimanifar F, Ardeshirylajimi A. The clinical trials of mesenchymal stem cell therapy in skin diseases: An update and concise review. Curr Stem Cell Res Ther 2019; 14(1): 22-33. doi: 10.2174/1574888X13666180913123424 PMID: 30210006
  15. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- Mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020; 11(2): 216-28. doi: 10.14336/AD.2020.0228 PMID: 32257537
  16. Bing L, Junhui C, Tao Li, Haiying Wu, Wenjie Y, Yanjiao Li, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. Medicine 2020; 99(31): e21429. doi: 10.12074/202002.00084
  17. Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 2020; 29(12): 747-54. doi: 10.1089/scd.2020.0080 PMID: 32380908
  18. Galea C, Riva N, Calleja-Agius J. Non-gynaecological applications of menstrual-derived stem cells: A systematic review. Avicenna J Med Biotechnol 2022; 14(1): 10-29. doi: 10.18502/ajmb.v14i1.8166 PMID: 35509365
  19. Chen S, Dong C, Zhang J, Tang B, Xi Z, Cai F, et al. Human menstrual blood-derived stem cells protect H9c2 cells against hydrogen peroxide-associated apoptosis. In Vitro Cell Dev Biol Anim 2019; 55(2): 104-12.
  20. Azedi F, Kazemnejad S, Zarnani AH, Soleimani M, Shojaei A, Arasteh S. Comparative capability of menstrual blood versus bone marrow derived stem cells in neural differentiation. Mol Biol Rep 2017; 44(1): 169-82. doi: 10.1007/s11033-016-4095-7 PMID: 27981446
  21. Khanjani S, Khanmohammadi M, Zarnani AH, et al. Comparative evaluation of differentiation potential of menstrual blood- versus bone marrow-derived stem cells into hepatocyte-like cells. PLoS One 2014; 9(2): e86075. doi: 10.1371/journal.pone.0086075 PMID: 24505254
  22. Skliutė G, Baušytė R, Borutinskaitė V, et al. Menstrual bloodderived endometrial stem cells’ impact for the treatment perspective of female infertility. Int J Mol Sci 2021; 22(13): 6774. doi: 10.3390/ijms22136774 PMID: 34202508
  23. Chang QY, Zhang SW, Li PP, Yuan ZW, Tan JC. Safety of menstrual blood-derived stromal cell transplantation in treatment of intrauterine adhesion. World J Stem Cells 2020; 12(5): 368-80. doi: 10.4252/wjsc.v12.i5.368 PMID: 32547685
  24. Chen L, Qu J, Xiang C. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Res Ther 2019; 10(1): 1. doi: 10.1186/s13287-018-1105-9 PMID: 30606242
  25. Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med 2020; 14(5): 664-73. doi: 10.1007/s11684-020-0810-9 PMID: 32761491
  26. Xu X, Jiang W, Chen L, et al. Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial. Clin Transl Med 2021; 11(2): e297. doi: 10.1002/ctm2.297 PMID: 33634996
  27. Lu J, Xie ZY, Zhu DH, Li LJ. Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature. World J Clin Cases 2021; 9(7): 1705-13. doi: 10.12998/wjcc.v9.i7.1705 PMID: 33728315
  28. Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, et al. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: Clinical trial phase I & II. Stem Cell Res Ther 2022; 13(1): 96. doi: 10.1186/s13287-022-02771-w PMID: 35255966
  29. Cao AJW, Jeyaraj D, Liu H. Co-administration of menstrual blood-derived stem cells and remdesivir for the treatment of severe coronavirus disease 2019 (COVID-19) induced pneumonia: A research protocol. URNCST J 2022; 6: 1-12. doi: 10.26685/urncst.319
  30. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581(7809): 465-9. doi: 10.1038/s41586-020-2196-x PMID: 32235945
  31. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1967-76. doi: 10.1056/NEJMoa030747 PMID: 12690091
  32. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367(19): 1814-20. doi: 10.1056/NEJMoa1211721 PMID: 23075143
  33. Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44. doi: 10.1038/s41564-020-0695-z PMID: 32123347
  34. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020; 583(7816): 459-68. doi: 10.1038/s41586-020-2286-9 PMID: 32353859
  35. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3. doi: 10.1038/s41586-020-2012-7 PMID: 32015507
  36. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8. doi: 10.1016/j.cell.2020.02.052 PMID: 32142651
  37. Zaki MM, Lesha E, Said K, et al. Cell therapy strategies for COVID-19: Current approaches and potential applications. Sci Adv 2021; 7(33): eabg5995. doi: 10.1126/sciadv.abg5995 PMID: 34380619
  38. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203(2): 631-7. doi: 10.1002/path.1570 PMID: 15141377
  39. Trougakos IP, Stamatelopoulos K, Terpos E, et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci 2021; 28(1): 9. doi: 10.1186/s12929-020-00703-5 PMID: 33435929
  40. Schoeman D, Fielding BC. Coronavirus envelope protein: Current knowledge. Virol J 2019; 16(1): 69. doi: 10.1186/s12985-019-1182-0 PMID: 31133031
  41. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat Rev Microbiol 2021; 19(3): 155-70. doi: 10.1038/s41579-020-00468-6 PMID: 33116300
  42. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8(9): 726-36. doi: 10.1038/nri2395 PMID: 19172693
  43. Novello S, Debouche A, Philippe M, Naudet F, Jeanne S. Clinical application ofmesenchymal stem cells in periodontalre generation: A systematic review and meta-analysis. J Periodontal Res 2020; 55(1): 1-12.
  44. Zhao K, Liu Q. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol 2016; 9(1): 46. doi: 10.1186/s13045-016-0276-z
  45. Chen J, Hu C, Chen L, et al. Clinical study of Mesenchymal stem cell treatment for acute respiratory distress syndrome induced by Epidemic Influenza A (H7N9) infection: A hint for COVID-19 treatment. Engineering 2020; 6(10): 1153-61. doi: 10.1016/j.eng.2020.02.006 PMID: 32292627
  46. Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: A randomized, placebo-controlled pilot study. Respir Res 2014; 15(1): 39. doi: 10.1186/1465-9921-15-39 PMID: 24708472
  47. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): A randomised phase 2a safety trial. Lancet Respir Med 2019; 7(2): 154-62. doi: 10.1016/S2213-2600(18)30418-1 PMID: 30455077
  48. Yip HK, Fang WF, Li YC, et al. Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome. Crit Care Med 2020; 48(5): e391-9. doi: 10.1097/CCM.0000000000004285 PMID: 32187077
  49. Simonson OE, Mougiakakos D, Heldring N, et al. In Vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med 2015; 4(10): 1199-213. doi: 10.5966/sctm.2015-0021 PMID: 26285659
  50. Kong Y, Shao Y, Ren C, Yang G. Endometrial stem/progenitor cells and their roles in immunity, clinical application, and endometriosis. Stem Cell Res Ther 2021; 12(1): 474. doi: 10.1186/s13287-021-02526-z PMID: 34425902
  51. Marinaro F, Gómez-Serrano M, Jorge I, et al. Unraveling the molecular signature of extracellular vesicles from endometrial-derived mesenchymal stem cells: Potential modulatory effects and therapeutic applications. Front Bioeng Biotechnol 2019; 7: 431. doi: 10.3389/fbioe.2019.00431 PMID: 31921832
  52. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013; 45(11): e54. doi: 10.1038/emm.2013.94 PMID: 24232253
  53. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: Cell biology to clinical progress. NPJ Regen Med 2019; 4(1): 22. doi: 10.1038/s41536-019-0083-6 PMID: 31815001
  54. Chow L, Johnson V, Impastato R, Coy J, Strumpf A, Dow S. Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells. Stem Cells Transl Med 2020; 9(2): 235-49. doi: 10.1002/sctm.19-0092 PMID: 31702119
  55. Wang S, Guo L, Ge J, et al. Excess integrins cause lung entrapment of mesenchymal stem cells. Stem Cells 2015; 33(11): 3315-26. doi: 10.1002/stem.2087 PMID: 26148841

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024